Accessibility Menu
Biodesix logo

Biodesix(NASDAQ) BDSX

Market Cap$227.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-91%
5 Year-88%
1 Year+149%
1 Month-5%
$22.49
+2.23%
+0.49Today
Biodesix last closing stock price
MetricPriceDate
Last closeUSD 22.222026-07-27
Biodesix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+12.17%USD 19.812026-07-20
1 month-4.8%USD 23.342026-06-26
3 month+123.32%USD 9.952026-04-28
Year to date+226.76%USD 6.802025-12-31
1 year+149.05%USD 8.922025-07-25
3 year+3.83%USD 21.402023-07-28
5 year-87.57%USD 178.802021-07-28
Since inception-91.41%USD 256.202020-10-28

Biodesix Financials at a Glance

Market Cap

$227.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$96.10M

Net Income (TTM)

-$31.96M

EPS (TTM)

-$4.03

P/E Ratio

-5.46

Dividend

$0.00

Beta (Volatility)

0.88 (Low)

Price

$22.49

Volume

2,646

Open

$22.68

Previous Close

$22.49

Daily Range

$22.46 - $23.17

52-Week Range

$5.26 - $24.92

Estimated Earnings Date

Aug 5, 2026

BDSX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biodesix

Biodesix, Inc. is a diagnostics company focused on developing innovative blood-based solutions primarily for lung cancer care. With a multi-omic strategy that incorporates genomics and proteomics, Biodesix aims to provide comprehensive insights into a patient's disease state, enhancing personalized treatment approaches and outcomes.

Products and Services

Nodify Lung Nodule Risk Assessment: Blood-based tests assessing lung nodule malignancy risk.

IQLung Testing Strategy: Includes GeneStrat ddPCR and GeneStrat NGS for tumor profiling and VeriStrat for immune response profiling.

Biopharma Services: Diagnostic research, clinical trial testing, and companion diagnostics development.

Diagnostic Technology Licensing: Revenue from licensing diagnostic technologies to third parties.

What Makes Biodesix, Inc. Special

Biodesix's unique multi-omic approach integrates genomic and proteomic data, providing a holistic understanding of disease states and facilitating personalized medicine. This differentiates Biodesix from competitors and positions it as a leader in precision diagnostics.

Five Things You Need to Know

Biodesix derives 92% of its revenue from its diagnostic testing business.

The company has commercialized five blood-based diagnostic tests for lung cancer.

Biodesix employs a multi-omic approach, utilizing genomics and proteomics in test development.

Biodesix has a biobank of biological specimens supporting research and development.

The company's diagnostics provide fast results, with the most tests reporting within three business days.

AI Generated • Apr 16, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

334

CEO

Scott Hutton

Website

www.biodesix.com

Headquarters

Louisville, CO 80301, US

BDSX Financials

Key Financial Metrics (TTM)

Gross Margin

82.08%

Operating Margin

-25.91%

Net Income Margin

-33.26%

Return on Equity

-2101.40%

Return on Capital

-39.45%

Return on Assets

-33.77%

Earnings Yield

-18.32%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$227.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

10.36M

Volume

2.65K

Avg. Volume

76.00K

Financials (TTM)

Gross Profit

$78.88M

Operating Income

-$24.90M

EBITDA

-$18.34M

Operating Cash Flow

-$24.84M

Capital Expenditure

-$411.00K

Free Cash Flow

-$25.25M

Cash & ST Invst.

$25.57M

Total Debt

$71.61M

Biodesix Performance Analysis

Biodesix annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 38,212,000-29.9%
20232023-12-31USD 49,087,00028.5%
20242024-12-31USD 71,323,00045.3%
20252025-12-31USD 88,499,00024.1%
Biodesix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3011.5%
Q32025-09-308.7%
Q42025-12-3132.1%
Q12026-03-31-11.1%
Biodesix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -31.09-1.4%
20232023-12-31USD -12.70-59.1%
20242024-12-31USD -6.62-47.9%
20252025-12-31USD -4.67-29.5%
Biodesix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-3027.5%
Q42025-12-3157.8%
Q12026-03-31-65.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$25.56M

+42.3%

Gross Profit

$21.35M

+49.8%

Gross Margin

83.55%

N/A

Market Cap

$227.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$682.12K

N/A

Employees

334

N/A

Net Income

-$7.79M

+29.8%

EBITDA

-$4.40M

+45.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$25.57M

+45.3%

Total Debt

$71.61M

+15.0%

Accounts Receivable

$9.50M

+24.4%

Inventory

$0.00

N/A

Long Term Debt

$70.16M

+14.7%

Short Term Debt

$1.45M

+30.8%

Return on Assets

-33.77%

N/A

Return on Invested Capital

-31.07%

N/A

Free Cash Flow

-$10.31M

-18.0%

Operating Cash Flow

-$10.17M

-18.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MRSNMersana Therapeutics, Inc.
$29.08+0.00%
XLOXilio Therapeutics, Inc.
$9.09+5.09%
OKUROnKure Therapeutics, Inc.
$4.05-1.70%
INMBINmune Bio, Inc.
$1.73+6.79%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About BDSX

What is the current price of Biodesix?

Biodesix is trading at $22.49 per share.

What is the 52-week range for Biodesix?

Over the past 52 weeks, Biodesix has traded between $5.26 and $24.92.

How much debt does Biodesix have?

As of the most recent reporting period, Biodesix reported total debt of $71.61M.

How much cash does Biodesix have on hand?

Biodesix reported $25.67M in cash and cash equivalents in its most recent financial results.

What is Biodesix’s dividend yield?

Biodesix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services